IMBDX Inc is a Korea-based company principally engaged in the provision of laboratory analysis services. The Company is principally engaged in the provision of laboratory analysis services such as clinical diagnosis services and genetic analysis services based on liquid biopsy technology. In addition, the Company is also engaged in the development, manufacture and sale of diagnostic products. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/11/26	KRW 2,445.00	+2.09%	10,401
30/10/26	KRW 2,395.00	0.00%	8,868
29/10/26	KRW 2,395.00	-3.23%	25,245
28/10/26	KRW 2,475.00	-1.39%	14,271
27/10/26	KRW 2,510.00	+1.41%	11,376

End-of-day quote Korea S.E.

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - IMB Dx, Inc.

Company calendar

End-of-day quote Korea S.E. 02/11/2026			5-day change	1st Jan Change
2,445.00 ^KRW	+2.09%		-1.21%	-75.28%

Market Cap	34.27B 25.49M 22.75M 20.88M 18.99M 35.61M 2.41B 36.32M 249M 101M 1.27B 95.65M 93.61M 4.02B	P/E 2024	-14.9x	P/E 2025	-17.5x
Enterprise Value	14.04B 10.44M 9.32M 8.55M 7.78M 14.59M 988M 14.88M 102M 41.18M 522M 39.18M 38.34M 1.65B	EV / Sales 2024	35.6x	EV / Sales 2025	22.2x
Free-Float	53.98%	Yield 2024 *	-	Yield 2025	-

1 day	+2.09%
1 week	-1.21%
Current month	+2.09%
1 month	-15.69%
3 months	-21.13%
6 months	-64.87%
Current year	-75.28%

1 week	2,285	2,530
1 month	2,285	3,060
Current year	1,910	11,260
1 year	1,910	12,950
3 years	1,910	40,550
5 years	1,910	40,550
10 years	1,910	40,550

Manager	Title	Age	Since
Tae-Yu Kim CEO	Chief Executive Officer	65	05/07/2018
Jin-Won Joo DFI	Director of Finance/CFO	52	-
Yong-Jun Cha CTO	Chief Tech/Sci/R&D Officer	-	-

IMB Dx, Inc. Stock

Stocks

A461030

KR7461030009

Biotechnology & Medical Research

Valuation: IMB Dx, Inc.

Chart: IMB Dx, Inc.

Latest news: IMB Dx, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: IMB Dx, Inc.

Latest insider transactions

Bio Diagnostics & Testing

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Director	Title	Age	Since
Tae-Yu Kim BRD	Director/Board Member	65	05/07/2018
Hwang-Pil Kim BRD	Director/Board Member	51	-
Ki-Won Yoon BRD	Director/Board Member	66	29/03/2023

Date	Insider	Type	Main position	Quantity	% Market Cap.
9/4/24	Hwang-Pil Kim	Free	Director	18,925	-
9/4/24	Soo-Yeon Kim	Free	Director	3,775	-
9/4/24	Tae-Yu Kim	Free	Founder	1,875,000	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMB DX, INC.	+2.09%	-1.21%	-77.69%	-	25.17M
WUXI APPTEC CO., LTD.	-2.37%	-5.03%	+39.49%	+62.39%	63.77B
ARGENX SE	-2.87%	+0.49%	+11.11%	+69.18%	56.37B
LONZA GROUP AG	+0.62%	+2.11%	+16.96%	+102.56%	54.62B
IQVIA HOLDINGS INC.	-3.33%	-5.54%	+19.39%	+35.69%	44.06B
BEONE MEDICINES AG	-2.45%	-2.59%	+16.36%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	-1.64%	+2.32%	+219.80%	+789.69%	41B
GENMAB A/S	-5.47%	+24.76%	+101.20%	+87.34%	34.92B
CELLTRION, INC.	+0.21%	+1.05%	+14.81%	+46.96%	32.82B
INSMED INCORPORATED	-2.90%	+17.12%	-42.35%	+337.07%	24.7B
Average	-1.81%	+5.89%	+31.91%	+181.04%	39.44B
Weighted average by Cap.	-2.16%	+4.83%	+44.62%	+163.55%

	2024	2025
Net sales	3.41B 2.53M 2.26M 2.08M 1.89M 3.54M 240M 3.61M 24.79M 9.99M 127M 9.51M 9.31M 400M	5.33B 3.96M 3.54M 3.25M 2.95M 5.54M 375M 5.65M 38.77M 15.63M 198M 14.87M 14.55M 625M
Net income	-9.58B -7.12M -6.36M -5.83M -5.31M -9.95M -674M -10.15M -69.68M -28.09M -356M -26.73M -26.16M -1.12B	-7.93B -5.9M -5.27M -4.83M -4.4M -8.24M -559M -8.41M -57.73M -23.27M -295M -22.14M -21.67M -931M
Net Debt	-28.12B -20.91M -18.67M -17.13M -15.58M -29.22M -1.98B -29.8M -205M -82.48M -1.04B -78.48M -76.81M -3.3B	-20.23B -15.05M -13.43M -12.33M -11.21M -21.02M -1.42B -21.44M -147M -59.35M -752M -56.47M -55.27M -2.37B